![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Virologic Outcomes with Tenofovir-Lamivudine-Dolutegravir for PI-Based Second-Line ART Failure
|
|
|
CROI 2024 March 3-6 Denver
Ying Zhao1,2, Jacqueline Voget3, Isaac Singini4, Zaayid Omar2, Vanessa Mudaly3, Andrew Boulle5, Gary Maartens2,6, Graeme Meintjes1,2
![0322241](../images/032224/032224-17/0322241.gif)
![0322242](../images/032224/032224-17/0322242.gif)
![0322243](../images/032224/032224-17/0322243.gif)
![0322244](../images/032224/032224-17/0322244.gif)
![0322245](../images/032224/032224-17/0322245.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|